Red Light Therapy and Eye Health: What the Research Actually Shows

Your retina is the most energy-hungry tissue in your body. Photoreceptors, and cone cells in particular, are dense with mitochondria, because turning light into a neural signal is metabolically expensive work that runs every waking second.

That has a consequence most people never hear about. Because the retina spends energy faster than anything else, it ages faster than anything else. Researchers at University College London put a figure on it: roughly a 70 percent reduction in retinal ATP production across a human lifetime, with a measurable decline in photoreceptor function following behind it.

Over the past few years the same group has been testing an unusual question. If the problem is failing mitochondria, and mitochondria happen to absorb long-wavelength light, can you shine light into an ageing eye and recover some function?

Why mitochondria respond to red light at all

Mitochondria are not indifferent to light. Cytochrome c oxidase, the enzyme at the end of the electron transport chain, absorbs strongly in the red and near-infrared range. Wavelengths spanning roughly 650 to 1000 nm have been shown to improve mitochondrial complex activity, membrane potential and ATP output.

That is the mechanism behind photobiomodulation in general. What makes the eye a compelling test case is that it has the most to gain, because it has the furthest to fall.

The UCL experiments

In 2020, Shinhmar and colleagues tested 670 nm light in people aged 28 to 72 and measured colour contrast sensitivity and rod thresholds. The results split neatly by age. In younger participants, the light did nothing measurable. In those around 40 and older, there were significant improvements in colour contrast sensitivity along the blue visual axis, the axis already known to be the most vulnerable to mitochondrial decline. Rod thresholds also improved significantly in the over-40s. The red axis improved too, but not significantly.

Published in The Journals of Gerontology: 10.1093/gerona/glaa155.

A follow-up in 2021, published in Scientific Reports, pushed further and found something more surprising. A single three-minute exposure, at far lower energy than the earlier work, improved cone-mediated colour contrast thresholds for a full week in participants aged 37 to 70. One short session, seven days of measurable effect. See 10.1038/s41598-021-02311-1.

Timing appears to matter more than dose

The 2021 paper included a caveat that is easy to skim past: the light has to be delivered at specific times of day.

The group followed this up in Journal of Biophotonics in 2022, tracking ATP production across a full 24-hour cycle. Production peaked in the morning, fell around midday, and stayed low through the afternoon and night. When 670 nm light was applied at 8am and 11am, ATP rose significantly. Applied at other times, it did nothing at all. The implication is that light-driven gains are only available when natural production is already high, so you are amplifying an existing peak rather than creating one. See 10.1002/jbio.202200093.

That study was done in fruit flies, so treat the specific hours as a hypothesis rather than a prescription. But it is a rare case of research explaining why a protocol might fail, rather than only reporting that it worked.

What this research does not show

This is where most articles on this subject overreach, so it is worth being precise.

• These were small studies. Tens of participants, not thousands. Encouraging, not settled.
• Colour contrast sensitivity is not the same as visual acuity. Nobody demonstrated that people could suddenly read further down an eye chart.
• This is not a treatment for macular degeneration or any other eye disease. The work measured age-related functional decline in people without diagnosed disease.
• The devices were purpose-built for ocular delivery. Participants looked into a specific 670 nm source under supervision. That is not the same as sitting in front of a full-body panel.
• There is no long-term safety or efficacy data for repeated ocular exposure over years.

Practical guidance, and one safety rule

The single most important point: do not look directly into a red light therapy panel. Body panels are built to deliver energy to skin and muscle across a large area, and are far more powerful than the low-energy ocular devices used in this research. Bright light sources can cause photochemical retinal injury.

If you are interested in light and eye health specifically, speak to an optometrist or ophthalmologist first, particularly if you have any existing eye condition, and keep your eyes closed or use eye protection during full-body sessions.

Common questions

Can red light therapy reverse age-related vision loss? No. The research shows short-term improvement in one specific measure of colour vision in people over 40. That is a long way from reversing vision loss.

Which wavelength was used? 670 nm, deep red, in every study described above.

How long were the sessions? Three minutes in the 2021 study, which found a week-long effect from a single exposure.

Does the time of day matter? The evidence suggests yes, with morning appearing to be the effective window, though that finding comes from an animal model.

Can I use a body panel for this? No. Never direct a body panel at open eyes.

Where this leaves things

The retina is an unusually good target for photobiomodulation, for a simple reason: it is the tissue where mitochondrial decline shows up earliest and most measurably. Small, well-designed studies from a serious research group have shown real, repeatable effects on one aspect of ageing vision.

That is genuinely interesting. It is not yet a treatment, and anyone selling it as one is ahead of the evidence.

If you are exploring red and near-infrared light for skin, recovery or general wellbeing, our Future Form systems deliver the wavelengths used across the photobiomodulation literature. For eyes specifically, talk to an eye care professional.